Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Natriuretic peptides as indicators of cardiac remodeling in hypertensive patients
Blood Pressure, 07/01/09
Magnusson M et al. – Findings show that natriuretic peptide levels increased with increasing number of markers of cardiac remodeling. N-terminal pro-atrial natriuretic peptide (Nt-ANP) and brain natriuretic peptide (BNP) are useful to discriminate between pts for cardiac remodeling and may be considered a screening tool to select pts eligible for further examination with echocardiography.
Methods- Study of the relationship between 3 different natriuretic peptides and left ventricular mass, function, and diameter and kidney function in hypertensive pts
- Subjects: 139 consecutive pts with moderate hypertension
- Analysis of Nt-BNP, BNP, and N-terminal pro-atrial natriuretic peptide (Nt-ANP)
- Echocardiography to assess cardiac remodeling
- Cystatin C to assess glomerular filtration
- Stratification by extent of cardiac remodeling: 1) no remodeling; 2) 1 of left ventricular hypertrophy, left ventricular dysfunction or left ventricular dilatation; 3) 2 of above and 4) all 3 parameters
- All peptides differed significantly between groups with a continuous stepwise increase from groups 1 through 4
- Receiver operating characteristic analysis showed equal diagnostic performances for detection of any cardiac abnormalities for Nt-BNP and BNP; both superior to Nt-ANP
- In multivariable linear regression analysis, all 3 indicators of cardiac remodeling independently correlated with Nt-BNP and BNP
- Only left ventricular diameter independently correlated with Nt-ANP
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis
Arthritis Care and Research , 11/03/09
Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment
Cardiovascular Drugs and Therapy, 11/03/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/23/09
Current options for the treatment of resistant hypertension
Expert Review of Cardiovascular Therapy , 11/13/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


